Privo Technologies (Privo), a Massachusetts-based company with roots in the Langer lab at MIT, has been selected to introduce its... read more

Peabody, MA– Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more

Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions to... read more

Privo Technologies, Inc., a clinical-stage biopharmaceutical company pioneering nanotechnology-based cancer therapies, is thrilled to announce the activation of multiple premier... read more

Privo Technologies attends BIO International Convention as an invited guest of the National Institute of Dental and Craniofacial Research Institute... read more

Watch Dr. Goldberg's presentation below regarding localized treatment of cancers in a more safe and effective way and the positive... read more

Privo Technologies, Inc.  attends the BIO International Convention online from June 14-18, 2021. Despite the conference being held online this year... read more

Peabody, MA -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy... read more

PEABODY, Mass., October 22, 2021 --Privo Technologies, Inc. ("Privo"), announced today the positive results of their Phase 1/2 clinical trial examining... read more

PEABODY, Mass., Sept. 24, 2020 -- Privo Technologies, Inc. ("Privo"), a biopharmaceutical company focused on breakthrough localized treatments for tough to treat mucosal... read more